• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Johnson & Johnson

Canada approves J&J Vision’s drug-eluting contact lens

April 27, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue Theravision

Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens. Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month. […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Johnson & Johnson, Johnson & Johnson Vision

J&J Vision wins Japanese approval for first drug-releasing contact lens

March 25, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue Theravision

Johnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen. The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release. Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the lens, […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Regulatory/Compliance Tagged With: Johnson & Johnson

FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

March 19, 2021 By Sean Whooley

Updated Janssen logo

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Federal Trade Commission (FTC), Johnson & Johnson

J&J’s Ethicon wins clearance for devices to deliver Grifols surgical sealant

June 19, 2019 By Chris Newmarker

Johnson & Johnson Ethicon Grifols

Johnson & Johnson’s Ethicon has won FDA clearance for airless spray devices to deliver Grifols’ fibrin sealant to stop surgical bleeding, the companies announced today. The Vistaseal fibrin sealant will be the first product Grifols (NSDQ:GRFS) is introducing with Johnson & Johnson (NYSE:JNJ) and Ethicon as part of a global partnership. The 510(k) clearance covers three Vistaseal […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Surgical Tagged With: Ethicon, Grifols, Johnson & Johnson

FDA approves J&J’s nasal spray for treatment-resistant depression

March 6, 2019 By Sarah Faulkner

Johnson & Johnson

The FDA has approved Johnson & Johnson‘s (NYSE:JNJ) esketamine nasal spray for people living with treatment-resistant depression. The company’s product, Spravato, is an intranasal formulation of ketamine – a horse tranquilizer that is also known as Special K. The drug won support for approval from an FDA advisory committee earlier this year. Spravato is the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: janssen, Johnson & Johnson

FDA committee backs J&J’s nasal spray for depression

February 13, 2019 By Sarah Faulkner

Updated Janssen logo

An FDA advisory committee has voted to support Johnson & Johnson‘s (NYSE:JNJ) Spravato esketamine nasal spray product as a therapy for adults living with treatment-resistant depression. J&J’s Janssen touted that if the U.S. regulatory agency decides to approve Spravato, it would be the first medicine in 30 years to sport a new mechanism of action […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Wall Street Beat Tagged With: janssen, Johnson & Johnson

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

Pills

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Valeant Pharmaceuticals

Layoffs ahead for nearly 300 in Pennsylvania as J&J winds down Animas

October 23, 2017 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) plans to lay off nearly 300 workers in Pennsylvania as it winds down its Animas insulin pump business. The layoffs for 297 are slated for Animas operations in West Chester and Wayne, Pa., effective Dec. 15, according to a notice filed with the Commonwealth’s Dept. of Labor & Industry. J&J announced the […]

Filed Under: Diabetes, Featured Tagged With: animas, Johnson & Johnson

  • « Go to Previous Page
  • Page 1
  • Page 2

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS